Andrey Doronichev
Founder & CEO, Optic. On 1 show, 1 appearance. The Shows tab opens the full record on each.
founderexecutiveinvestorauthor@dobry ↗LinkedIn ↗doronichev.com ↗
Doronichev leads Optic (Bioptic), an AI company building platforms to accelerate preclinical drug discovery. He previously spent over a decade at Google as Head of Mobile at YouTube and Director of Product for AR/VR and Stadia, and is an active angel investor and author.
1shows
1appearances
13statements
1resolved
1supported
0contradicted
100%fully supported
Everything Andrey Doronichev said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Doronichev: Google Stadia failed due to a lack of organizational focus
“Google didn't have enough attention to focus on this project. It didn't have enough resources to dedicate to it. And as a result, it failed despite, you know, all the resources.”
Doronichev: Every pharma company will become AI-native within 10 years or fail
“Within the next 10 years, every pharma will become an AI native pharma. Just like every retailer turned into e-commerce or left the market within the first 10 years of the internet.”
Doronichev: Scientific research is not the primary bottleneck in pharma commercialization
“Science is not really a bottleneck in, in most cases. Getting, there's plenty of great research out there, and there are many ways researchers are discovering molecules, but getting from a great research paper to an actual drug that helps treat patients and ge…”
Doronichev: Fully automated AI hedge funds will emerge to trade biotech
“I believe this is going to happen. We're going to have fully automated end-to-end first probably hedge funds or investment companies that would be full in the fully automated fashion, deeply analyzing scientific and business details of companies out there and …”
Doronichev: Consumer AI models fall short for multi-million-dollar life science decisions
“Those are consumer grade AI systems that make a lot of our tasks easier, right? But when it comes to business and especially life sciences business applications, they often come short. Specifically there are special metrics in AI world, precision, recall hallu…”
Doronichev: YouTube App's Success Was Driven Primarily by Underlying ML
“I think the major reason this product became so successful had to do with machine learning infrastructure that was completely under the surface and really hard to see.”
Doronichev: Scientific Papers Enable Startups to Bypass Biopharma Relationship Networks
“So I guess the lesson for fellow founders here, yes, you might be disadvantaged in terms of, you know, whether or not you play golf with the CEO of Pfizer and it might feel like it's impossible to penetrate this big pharma world. However, if your research matt…”
Doronichev: UCSF pilots Bioptic AI agents to curate Protein Data Bank
“And by the way, to plug us in here, I'm really proud to say that UCSF, who is curating PDB, is now using, they've been piloting bioptics since last year, and they're using our agents to automate this process, to actually monitor every paper in every language, …”
Doronichev: Early drug discovery represents only $100B of the $2T pharma market
“Pharma is a two trillion dollar industry. Of that trillion dollar, only a hundred billion dollars is in drug discovery, so this early stage. A hundred bill out of two trillion is a tiny fraction”
Doronichev: Fully autonomous AI pharma operating system is 10-20 years away
“The holy grail of AI scientists. So the automated system that makes its own scientific hypotheses, And then conducts experiments, you know, maybe manipulating robotic lab and then feeding this data back into the system, making better decisions, more hypotheses…”
Bioptic combines neural networks and agents to act as junior biotech analysts
“We have built a full layer of scientific neural nets and over it a layer of agentic scaffolding that turns modern reasoning models into what you might consider a junior biotech analyst.”
Doronichev: Isomorphic Labs Cold-Contacted Bioptic Over AI Research Paper
“After we published this paper, Google's isomorphic, which is probably the coolest AI drug discovery company out there in terms of technology discovered it and contacted us through the website cold asking questions about it.”
One line per show, most statements first. The link opens Andrey's full record on that show: the calibration, argument clarity, speaking style and every statement made there.
| Show | Role there | Eps | Statements | Record | |
|---|---|---|---|---|---|
 INNOVATORS & INVESTORSLEDGER | Founder & CEO, Optic | 1 | 13 | 100% 1/1 | full record on Innovators & Investors → |